+44 20 8123 2220
info@marketpublishers.com

Nonmuscle invasive bladder cancer - Pipeline Insight, 2021

https://marketpublishers.com/r/NAA18BBB78CEN.html
Date: July 2021
Pages: 80
Price: US$ 2,000.00 (Single User License)
ID: NAA18BBB78CEN

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "Nonmuscle invasive bladder cancer - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nonmuscle invasive bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Nonmuscle invasive bladder cancer Understanding

Nonmuscle invasive bladder cancer: Overview

Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and

intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.

'Nonmuscle invasive bladder cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nonmuscle invasive bladder cancer pipeline landscape is provided which includes the disease overview and Nonmuscle invasive bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Nonmuscle invasive bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonmuscle invasive bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nonmuscle invasive bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Nonmuscle invasive bladder cancer.

Nonmuscle invasive bladder cancer Emerging Drugs Chapters

This segment of the Nonmuscle invasive bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nonmuscle invasive bladder cancer Emerging Drugs

UGN-102: UroGen Pharma

UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative

technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UGN-102 is in Phase III clinical evaluation for the treatment of Nonmuscle invasive bladder cancer.

Sasanlimab: Pfizer

Sasanlimab (PF-06801591) is an immunotherapy that Pfizer is developing for several types of cancer. It is called an anti-PD-1 treatment because it blocks the PD-1 protein on the surface of immune T-cells that can sometimes attack healthy cells. PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. Pfizer is developing PF-06801591 for the treatment of Non-muscle Invasive Bladder Cancer and is currently in phase III stage of development.

Further product details are provided in the report……..

Nonmuscle invasive bladder cancer: Therapeutic Assessment

This segment of the report provides insights about the different Nonmuscle invasive bladder cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nonmuscle invasive bladder cancer

There are approx. 30+ key companies which are developing the therapies for Nonmuscle invasive bladder cancer. The companies which have their Nonmuscle invasive bladder cancer drug candidates in the most advanced stage, i.e. Phase III include, UroGen Pharma.

Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Nonmuscle invasive bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nonmuscle invasive bladder cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nonmuscle invasive bladder cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonmuscle invasive bladder cancer drugs.

Nonmuscle invasive bladder cancer Report Insights

Nonmuscle invasive bladder cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Nonmuscle invasive bladder cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

+44 20 8123 2220
info@marketpublishers.com

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Nonmuscle invasive bladder cancer drugs?

How many Nonmuscle invasive bladder cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nonmuscle invasive bladder cancer?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nonmuscle invasive bladder cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Nonmuscle invasive bladder cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

UroGen Pharma

CG Oncolgy

Sasanlimab

Sesen Bio

+44 20 8123 2220
info@marketpublishers.com

Theralase Technologies

Asieris Pharmaceuticals

Hamlet Pharma

AstraZeneca

Viralytics

ImmunityBio

Prokarium

Vaxiion Therapeutics

Janssen Pharmaceuticals

Abraxis Bioscience

LIPAC Oncology

Rapamycin Holdings

Incyte Corporation

Taizhou Hanzhong biomedical

Key Products

UGN-102

CG 0070

Pfizer

Vicineum

+44 20 8123 2220
info@marketpublishers.com

TLD-1433

APL-1202

Alpha1H

Durvalumab

CVA 21

Inbakicept

Vesibax

VAX-014

Balversa

ABI-009

TSD-001

eRapa

Pemigatinib

HX008

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Executive Summary
Nonmuscle invasive bladder cancer: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Nonmuscle invasive bladder cancer – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
  Comparative Analysis
UGN-102: UroGen Pharma
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
TLD 1433: Theralase Technologies
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
VAX-014: Vaxiion Therapeutics
  Product Description
  Research and Development

+44 20 8123 2220
info@marketpublishers.com

Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Vesibax: Prokarium
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nonmuscle invasive bladder cancer Key Companies
Nonmuscle invasive bladder cancer Key Products
Nonmuscle invasive bladder cancer- Unmet Needs
Nonmuscle invasive bladder cancer- Market Drivers and Barriers
Nonmuscle invasive bladder cancer- Future Perspectives and Conclusion
Nonmuscle invasive bladder cancer Analyst Views
Appendix

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1 Total Products for Nonmuscle invasive bladder cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Nonmuscle invasive bladder cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Nonmuscle invasive bladder cancer - Pipeline Insight, 2021

Product link: https://marketpublishers.com/r/NAA18BBB78CEN.html

Price: US$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/NAA18BBB78CEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970